Atul Bedi
YOU?
Author Swipe
View article: Supplementary Figure 1 from Inhibition of TGF-β Enhances the <i>In Vivo</i> Antitumor Efficacy of EGF Receptor–Targeted Therapy
Supplementary Figure 1 from Inhibition of TGF-β Enhances the <i>In Vivo</i> Antitumor Efficacy of EGF Receptor–Targeted Therapy Open
PDF file - 191K, Tumor HPV status and serum TGF-beta1 levels of HNSCC patients
View article: Data from Inhibition of TGF-β Enhances the <i>In Vivo</i> Antitumor Efficacy of EGF Receptor–Targeted Therapy
Data from Inhibition of TGF-β Enhances the <i>In Vivo</i> Antitumor Efficacy of EGF Receptor–Targeted Therapy Open
EGF receptor (EGFR)–targeted monoclonal antibodies (mAb), such as cetuximab, execute their antitumor effect in vivo via blockade of receptor–ligand interactions and engagement of Fcγ receptors on immune effector cells that trigger antibody…
View article: Supplementary Figure 1 from Inhibition of TGF-β Enhances the <i>In Vivo</i> Antitumor Efficacy of EGF Receptor–Targeted Therapy
Supplementary Figure 1 from Inhibition of TGF-β Enhances the <i>In Vivo</i> Antitumor Efficacy of EGF Receptor–Targeted Therapy Open
PDF file - 191K, Tumor HPV status and serum TGF-beta1 levels of HNSCC patients
View article: Supplementary Table 2 from Inhibition of TGF-β Enhances the <i>In Vivo</i> Antitumor Efficacy of EGF Receptor–Targeted Therapy
Supplementary Table 2 from Inhibition of TGF-β Enhances the <i>In Vivo</i> Antitumor Efficacy of EGF Receptor–Targeted Therapy Open
PDF file - 70K, A, Serum levels of the indicated cytokines in patients with HNSCC and pleomorphic adenoma (non-cancer control). B, Comparison of serum TGF-beta1 levels in non-cancer controls and patients with HNSCC at the time of new diagn…
View article: Supplementary Table 2 from Inhibition of TGF-β Enhances the <i>In Vivo</i> Antitumor Efficacy of EGF Receptor–Targeted Therapy
Supplementary Table 2 from Inhibition of TGF-β Enhances the <i>In Vivo</i> Antitumor Efficacy of EGF Receptor–Targeted Therapy Open
PDF file - 70K, A, Serum levels of the indicated cytokines in patients with HNSCC and pleomorphic adenoma (non-cancer control). B, Comparison of serum TGF-beta1 levels in non-cancer controls and patients with HNSCC at the time of new diagn…
View article: Supplementary Table 1 from Inhibition of TGF-β Enhances the <i>In Vivo</i> Antitumor Efficacy of EGF Receptor–Targeted Therapy
Supplementary Table 1 from Inhibition of TGF-β Enhances the <i>In Vivo</i> Antitumor Efficacy of EGF Receptor–Targeted Therapy Open
PDF file - 256K, Clinical characteristics of patients with HNSCC
View article: Data from Inhibition of TGF-β Enhances the <i>In Vivo</i> Antitumor Efficacy of EGF Receptor–Targeted Therapy
Data from Inhibition of TGF-β Enhances the <i>In Vivo</i> Antitumor Efficacy of EGF Receptor–Targeted Therapy Open
EGF receptor (EGFR)–targeted monoclonal antibodies (mAb), such as cetuximab, execute their antitumor effect in vivo via blockade of receptor–ligand interactions and engagement of Fcγ receptors on immune effector cells that trigger antibody…
View article: Supplementary Table 1 from Inhibition of TGF-β Enhances the <i>In Vivo</i> Antitumor Efficacy of EGF Receptor–Targeted Therapy
Supplementary Table 1 from Inhibition of TGF-β Enhances the <i>In Vivo</i> Antitumor Efficacy of EGF Receptor–Targeted Therapy Open
PDF file - 256K, Clinical characteristics of patients with HNSCC
View article: Supplemental Figure 2 from SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells
Supplemental Figure 2 from SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells Open
Western blot analysis of SCC61L-SC and SMAD4KD cells for phospho-SMAD2 and total SMAD2/3 expression levels. Actin was used as a loading control.
View article: Suppl Fig Table Legends from SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells
Suppl Fig Table Legends from SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells Open
Supplemental figure and table legends
View article: Supplemental Figure 2 from SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells
Supplemental Figure 2 from SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells Open
Western blot analysis of SCC61L-SC and SMAD4KD cells for phospho-SMAD2 and total SMAD2/3 expression levels. Actin was used as a loading control.
View article: Supplemental Table 1-3 from SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells
Supplemental Table 1-3 from SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells Open
Supplemental Table 1. Summary of patient characteristics with newly diagnosed HNSCC. Supplemental Table 2. Summary of patient characteristics with recurrent and/or metastatic HNSCC. Supplemental Table 3. Injection of FaDu-SMAD4 cells resul…
View article: Figure S1 from SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells
Figure S1 from SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells Open
Representative SMAD4 IHC, FaDu negative control, SCC25/SCC61 positive control.
View article: Data from SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells
Data from SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells Open
Purpose: We previously demonstrated an association between decreased SMAD4 expression and cetuximab resistance in head and neck squamous cell carcinoma (HNSCC). The purpose of this study was to further elucidate the clinical relevance of S…
View article: Supplemental Figure 5 from SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells
Supplemental Figure 5 from SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells Open
Matrigel colony formation assay of FaDu-mock and FaDu-SMAD4 cells treated with PBS or Cetuximab in combination with JNKi (SP600125) or MEKi (U0126) at indicated concentrations for 7 days. (*p<0.05 and **p<0.01 compared to FaDu-mock and FaD…
View article: Suppl Fig Table Legends from SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells
Suppl Fig Table Legends from SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells Open
Supplemental figure and table legends
View article: Data from SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells
Data from SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells Open
Purpose: We previously demonstrated an association between decreased SMAD4 expression and cetuximab resistance in head and neck squamous cell carcinoma (HNSCC). The purpose of this study was to further elucidate the clinical relevance of S…
View article: Supplemental Figure 3 from SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells
Supplemental Figure 3 from SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells Open
(A) Western blot confirming the knockdown of SMAD4 levels by stable expression of short-hairpin RNA in SCC25 cell line. (SC: scrambled control shRNA, SMAD4KD: shRNA against SMAD4). (B) Matrigel colony formation assay was performed for SCC2…
View article: Supplemental Figure 4 from SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells
Supplemental Figure 4 from SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells Open
FaDu-mock and FaDu-SMAD4 cells were serum starved for 24 hours and then incubated with DMSO or JNK inhibitor (SP600125) for 24 hours. Cell lysates were analyzed by (A) western blot for SMAD4, total and phosphorylated JNK (T183/Y185), and G…
View article: Supplemental Figure 3 from SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells
Supplemental Figure 3 from SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells Open
(A) Western blot confirming the knockdown of SMAD4 levels by stable expression of short-hairpin RNA in SCC25 cell line. (SC: scrambled control shRNA, SMAD4KD: shRNA against SMAD4). (B) Matrigel colony formation assay was performed for SCC2…
View article: Supplemental Figure 4 from SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells
Supplemental Figure 4 from SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells Open
FaDu-mock and FaDu-SMAD4 cells were serum starved for 24 hours and then incubated with DMSO or JNK inhibitor (SP600125) for 24 hours. Cell lysates were analyzed by (A) western blot for SMAD4, total and phosphorylated JNK (T183/Y185), and G…
View article: Supplemental Figure 5 from SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells
Supplemental Figure 5 from SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells Open
Matrigel colony formation assay of FaDu-mock and FaDu-SMAD4 cells treated with PBS or Cetuximab in combination with JNKi (SP600125) or MEKi (U0126) at indicated concentrations for 7 days. (*p<0.05 and **p<0.01 compared to FaDu-mock and FaD…
View article: Figure S1 from SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells
Figure S1 from SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells Open
Representative SMAD4 IHC, FaDu negative control, SCC25/SCC61 positive control.
View article: Supplemental Table 1-3 from SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells
Supplemental Table 1-3 from SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells Open
Supplemental Table 1. Summary of patient characteristics with newly diagnosed HNSCC. Supplemental Table 2. Summary of patient characteristics with recurrent and/or metastatic HNSCC. Supplemental Table 3. Injection of FaDu-SMAD4 cells resul…
View article: Supplementary Table 1 from The TGFβ–miR200–MIG6 Pathway Orchestrates the EMT-Associated Kinase Switch That Induces Resistance to EGFR Inhibitors
Supplementary Table 1 from The TGFβ–miR200–MIG6 Pathway Orchestrates the EMT-Associated Kinase Switch That Induces Resistance to EGFR Inhibitors Open
PDF file - 2202KB, Summary of EGFR, KRAS, NRAS and P53 mutation status in 18 human NSCLCs and 27 pancreatic directly xenografted low passage tumors.
View article: Supplementary Figure 3 from The TGFβ–miR200–MIG6 Pathway Orchestrates the EMT-Associated Kinase Switch That Induces Resistance to EGFR Inhibitors
Supplementary Figure 3 from The TGFβ–miR200–MIG6 Pathway Orchestrates the EMT-Associated Kinase Switch That Induces Resistance to EGFR Inhibitors Open
PDF file - 127KB, Levels of Mig6 protein in the panel of 25 human cancer cell lines with known erlotinib resistance was identified by immunoblot analysis followed by densitometric quantification. The expression level of Mig6 was plotted ag…
View article: Supplementary Figure 2 from The TGFβ–miR200–MIG6 Pathway Orchestrates the EMT-Associated Kinase Switch That Induces Resistance to EGFR Inhibitors
Supplementary Figure 2 from The TGFβ–miR200–MIG6 Pathway Orchestrates the EMT-Associated Kinase Switch That Induces Resistance to EGFR Inhibitors Open
PDF file - 108KB, TGFbeta induces EMT-associated kinase switch promotes erlotinib-resistance of tumor cells. A. Erlotinib sensitive cell lines H292 and SCC-S were treated with TGFβ1 (4 ng/ml) for 21 days and immunoblot analysis was perform…
View article: Supplementary Figure Legends from The TGFβ–miR200–MIG6 Pathway Orchestrates the EMT-Associated Kinase Switch That Induces Resistance to EGFR Inhibitors
Supplementary Figure Legends from The TGFβ–miR200–MIG6 Pathway Orchestrates the EMT-Associated Kinase Switch That Induces Resistance to EGFR Inhibitors Open
PDF file - 197KB
View article: Supplementary Figure 5 from The TGFβ–miR200–MIG6 Pathway Orchestrates the EMT-Associated Kinase Switch That Induces Resistance to EGFR Inhibitors
Supplementary Figure 5 from The TGFβ–miR200–MIG6 Pathway Orchestrates the EMT-Associated Kinase Switch That Induces Resistance to EGFR Inhibitors Open
PDF file - 199KB, RNA was extracted from 18 human NSCLCs and 27 pancreatic directly xenografted low passage tumors. Levels of miR200c were measured by quantitative RT-PCR and mRNA levels of Mig6 and EGFR were determined by Affymetrix expre…
View article: Supplementary Figure 1 from The TGFβ–miR200–MIG6 Pathway Orchestrates the EMT-Associated Kinase Switch That Induces Resistance to EGFR Inhibitors
Supplementary Figure 1 from The TGFβ–miR200–MIG6 Pathway Orchestrates the EMT-Associated Kinase Switch That Induces Resistance to EGFR Inhibitors Open
PDF file - 2120KB, FAK activity is significantly higher in erlotinib-resistant cells from lung and H and N origin. Total cell lysates were extracted from two pairs of lung (H358/H1703 and Calu3/Calu6) and two pairs of H and N (SCC-S/SCC-R …